Business
Parsortix enables CTC molecular characterisation
Parsortix enables CTC molecular characterisation.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 6487X Angle PLC 28 November 2017 \n\n\n\n\n\nFor immediate release\n\n\n 28 November 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \n \nPARSORTIXTM SYSTEM ENABLES MOLECULAR DETECTION AND CHARACTERISATION OF CIRCULATING TUMOUR CELLS WHERE OTHER APPROACHES FAIL \n \nResults demonstrate that harvested CTCs can be analysed without further purification steps \n \nStudy published in eighth peer reviewed paper detailing ParsortixTM use\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its ParsortixTM system is the subject of a further peer-reviewed publication in the journal Oncotarget, detailing work undertaken by Prof. Robert Zeillinger's Molecular Oncology Group at the Medical University of Vienna (Vienna). Prof. Zeillinger is a key opinion leader in the field of liquid biopsies use in oncology.\n \nProf Zeillinger's group developed and tested protocols to allow the molecular characterisation of the circulating tumour cells (CTCs) and residual blood cells harvested by the ParsortixTM system without the need to separate out the CTCs. This was only possible because the ParsortixTM system provides high purity cells with very efficient removal of white blood cells. With alternative approaches for CTC enrichment such as density gradient centrifugation, this has not been possible, as high levels of contaminating white blood cells remain with the CTCs captured. \n \nVienna had identified specific genes which were expressed preferentially on CTCs earlier and, evaluating a panel of such genes, were able to get positive results in 95% of primary (i.e. localised disease that has not spread) gynaecological cancer patient samples, 100% of recurrent gynaecological cancer patient samples and 92% metastatic breast cancer patient samples.\n \nThis workflow established by Prof. Zeillinger's group provides the opportunity not only for use in detection of cancer but also the molecular characterisation of CTCs for the purpose of assessing which drugs may be most effective for a patient during their disease progression.\n \nThe publication is available at https://angleplc.com/library/publications/\n \nProfessor Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna, commente...